MIDDLES

Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85

C Smit, F R Rosendaal, I Varekamp, A Brocker-Vriends, H Van Dijck, Th P B M Suurmeijer, E Briët

Abstract
A study was carried out among haemophiliacs in The Netherlands to evaluate the effect of modern substitution treatment (replacing the missing clotting factors) on medical and social performance. Three questionnaires were sent between 1972 and 1985. The use of prophylactic treatment in the group of patients with severe and moderately severe haemophilia increased from 21% (n=242) in 1972 to 36% (n=559) in 1985. Home treatment programmes increased from 4% to 53%. Overall mortality was 2-1 times higher than in the general male population, which leads to a calculated life expectancy of 66 years compared with 74 years in the general male population. Severe joint impairment was prominent in the older age groups, reflecting insufficient treatment in the past. A sharp decrease in the use of inpatient and outpatient hospital facilities was observed as well as much less absence from school and work.

It is concluded that the high costs of modern substitution treatment are fully justified.

Introduction
Before modern substitution treatment was introduced at the end of the 1960s haemophilia caused premature death and severe disability at a young age. The possibility of a person with haemophilia enjoying a full social life was non-existent or limited. The availability of clotting factor concentrates and the introduction of home treatment have greatly improved the quality of life of patients with haemophilia and their families. The feelings of optimism that resulted from this development have, however, gradually disappeared with the occurrence of diseases that are associated with transfusion, such as hepatitis and AIDS.

Unlike patients in hospital who receive a few or just one transfusion with full blood or blood components haemophiliacs receive during their life many transfusions of clotting factor VIII or IX, which they lack. This so called substitution or replacement treatment is given on demand (when bleeding occurs) or as a prophylaxis. It is this repeated substitution treatment that makes haemophiliacs so susceptible to diseases associated with transfusion, especially when the clotting factor concentrates are made from large pools of donor blood.

The side effects of transfusion, together with the cost of treating haemophiliacs and the growing pressure on health care budgets, may cause people to question whether the benefits of substitution treatment still outweigh the disadvantages. A few studies only have dealt with this question and they have been limited to small numbers of patients or to one aspect—for instance, the introduction of home treatment or employment. Moreover, these studies concerned single treatment networks so that the conclusions may not be generalised.

The aim of our study was to evaluate modern haemophilia treatment in The Netherlands. Therefore, we reviewed the medical and social performance of Dutch haemophiliacs by means of questionnaires sent out in 1972, 1978, and 1985.

Methods
We carried out three postal surveys among Dutch haemophiliacs in 1972, 1978, and 1985. The first was based on a haemophilia questionnaire used by the Children's Orthopedic Hospital in Los Angeles, California. The questionnaire was prestructured (multiple choice) and had some open questions. The standardised questionnaires covered a broad range of aspects of haemophilia—for example, type and severity, number of bleedings, transfusion treatment, treatment regimens, orthopaedic state, hospital admissions, education, disability and employment, insurance, social relations, genetic counselling, and so on. Many items were repeated in the second and third surveys, while questions on some current topics, such as home treatment (second) and infection with HIV (human immunodeficiency virus) (third) were added. Patients or their parents were reached through the Dutch Haemophilia Society, treatment centres, and notices in the press. When necessary the information from the patients' questionnaires was supplemented with data from the haemophilia treatment centres. Cumulative data refer to the one year period directly preceding the mailing of the questionnaires.

Figures on mortality were calculated for the respondents in either one or both of the first two surveys, with follow up extending up to 1 January 1986. These formed a group of 717 patients; none was lost to follow up. Mortality was calculated by life table method and compared with the mortality of a hypothetical cohort of the general male population with a similar age distribution. These and other data for the general male population were provided by the Central Bureau for Statistics and the Department of Social Affairs and Employment.

Joint impairment for 16 joints was scored as follows: 0, no impairment of the joint; 1, some impairment but no daily problems; 2, impairment with daily problems; 3, impairment with complete loss of function. The total score ranged from 0 to 48 points.

Of the 935 participants in the 1985 survey 567 (61%) had also participated in one of the earlier surveys. Of the 376 patients with mild haemophilia in the 1985 survey, 207 (55%) were new participants, in contrast to 91 (24%) and 70 (40%) patients with severe and moderately severe haemophilia respectively. To allow data from the three surveys to be compared we decided...
to exclude the patients with mild haemophilia from the analysis. We investigated whether a "healthier new patients effect" still existed—that is, whether the patients in the 1985 survey who had not participated in the earlier surveys were healthier than those who had participated before, which would of course lead to an overoptimistic view. As a measure for comparison we used the score on joint impairment, as defined above.

Table 1 shows the score for joint impairment for patients who were new participants and those who also participated in 1972 or 1978, stratified by age. The observed differences in joint score were small and not significant (p<0.05).

Table 1—Scores for joint impairment: patients participating for the first time (new) in the 1985 survey compared with those who participated in one of the earlier surveys (old)

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Old patients (n=589)</th>
<th>New patients (n=92)</th>
<th>Difference</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-19</td>
<td>86 1 79</td>
<td>36 1 90</td>
<td>0.29</td>
<td>-0.63 to 1.21</td>
</tr>
<tr>
<td>20-34</td>
<td>159 5.5%</td>
<td>27 4.5%</td>
<td>1.03</td>
<td>-1.02 to 3.08</td>
</tr>
<tr>
<td>35+</td>
<td>144 10.40</td>
<td>29 6.52</td>
<td>3.88</td>
<td>-1.12 to 6.88</td>
</tr>
</tbody>
</table>

Note: The age groups were chosen to form about equal sized subgroups in the "new" patients group. The youngest patients were excluded since they could not have participated in one of the earlier surveys. For all three age groups the differences in the mean joint scores were small and not significant (p<0.05) as the 95% confidence interval of the difference enclosed zero.

Results

Response—The response to the questionnaires was 84% in 1972 (447 participants), 70% in 1978 (560 participants), and 81% in 1985 (935 participants from 1162 questionnaires mailed). With an estimated prevalence of 8.5 per 100000 population and a total population of 14.5 million Dutch we reached more than 90% of all Dutch haemophiliacs in 1985, and three quarters responded to the survey.

In 1985, 801 (85%) respondents had haemophilia A, 132 (15%) haemophilia B, and two patients had a factor VII and factor XIII deficiency, respectively. This distribution was similar in the first two surveys. In 1985, 384 (40%) had severe, 175 (20%) moderately severe, and 376 (40%) mild haemophilia; 19 (5%) patients with severe haemophilia had an inhibitor, and another 12 mentioned that their one time inhibitor had been eradicated.

Treatment—Both prophylactic treatment and home treatment have increased enormously since 1972 (table II) in the group with severe and moderately severe haemophilia. The average number of manifest bleedings decreased from 19 a year in 1972 and 1978 to 13 a year in 1985, with a corresponding decline in the number of transfusions needed for treatment on demand. For comparison, those with mild haemophilia reported one bleed a year in 1985. In the group with severe and moderately severe haemophilia substitution treatment for 495 (89%) patients consisted of clotting factor concentrates prepared by the Dutch Red Cross blood transfusion services; 35 (6%) of the respondents were treated with commercially produced imported concentrates, whereas 29 received no treatment. The market share of the commercially produced imported concentrates proved somewhat higher in the survey of 1978 but then declined, probably owing to the risk of HIV infection.

Life expectancy—We found an overall mortality (43 deaths) 2.1 times higher than would have occurred in a group of non-haemophiliacs of the same age distribution. This excess mortality in haemophilia leads to a calculated median life expectancy of 66 years (general male population: 74 years), when an equal distribution of excess mortality over age is assumed. Most improvement has been made in severe haemophilia, and now almost equal death rates apply for severe, moderate, and mild haemophilia. Patients with an inhibitor had a far less favourable prognosis, with a risk of death five times higher than the severely affected haemophiliacs without an inhibitor.

HIV—In our latest survey more than a third (134) of all patients with severe haemophilia had been tested for antibodies to HIV compared with 41 (23%) and 40 (11%) of the patients with moderately severe and mild haemophilia, respectively. The overall seropositivity was 17% (36 of 217), with the highest prevalence (21%) of HIV antibodies among patients with severe haemophilia.

Joint impairment—Looking at the total score of joint impairment in 1985 we saw that 58 (15%) of the patients with severe haemophilia reported no joint damage at all compared with 68 (39%) and 224 (60%) of those with moderately severe and mild haemophilia.

Almost half (281) of the patients with severe and moderately severe haemophilia had a score of 1 to 7 of a total of 48 points. One in every three patients with severe haemophilia had nine or more points, which implies three joints with complete loss of all function or another 12 mentioned that their one time inhibitor had been eradicated.

Figure 1 shows the score for joint impairment for patients who were new participants and those who also participated in 1972 or 1978, stratified by age. The observed differences in joint score were small and not significant (p<0.05) as the 95% confidence interval of the difference enclosed zero.

Table II—Type of treatment given to patients with severe and moderately severe haemophilia. Figures are numbers (and percentages)

<table>
<thead>
<tr>
<th></th>
<th>1972 (n=384)</th>
<th>1978 (n=551)</th>
<th>1985 (n=559)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment*</td>
<td>33 (14)</td>
<td>34 (10)</td>
<td>29 (5)</td>
</tr>
<tr>
<td>Treatment on demand</td>
<td>157 (65)</td>
<td>201 (57)</td>
<td>329 (59)</td>
</tr>
<tr>
<td>Prophylactic treatment</td>
<td>52 (21)</td>
<td>116 (33)</td>
<td>201 (36)</td>
</tr>
<tr>
<td>Home treatment</td>
<td>9 (4)</td>
<td>88 (25)</td>
<td>298 (53)</td>
</tr>
</tbody>
</table>

*Those who received no treatment because of no bleedings, the presence of an inhibitor, or accessibility of treatment facilities.

almost half (281) of the patients with severe and severely severe haemophilia had a score of 1 to 7 of a total of 48 points. One in every three patients with severe haemophilia had nine or more points, which implies three joints with complete loss of all function or several joints with minor damage. To illustrate the impact of the severity of haemophilia we calculated in the figure the median score of joint impairment for severe, moderately severe, and mild haemophilia. The median score on joint impairment was highest in the older age groups.

Use of hospital facilities—In 1985 the average use of inpatient hospital facilities was four days per patient a
year in the group with severe and moderately severe haemophilia compared with one day for the general Dutch male population. In 1972 this difference was still 21 days. In 1972 one out of every two patients needed to go to hospital, in contrast to one out of every four in 1985. For those who went into hospital the average number of days spent in hospital dropped from 49 days in 1972 to 16 days in 1985, which was near to the national average of 13 days for men (table III).

The number of transfusions performed at home rose from 996 in 1972 to 29 680 in 1985. Therefore, the number of outpatient visits to the hospital decreased substantially.

Social participation—Table IV shows the improvement in social participation, as judged by absence from school and work. The educational level of the survey population in 1985 was not different from that of the general male population. For the respondents aged 15 to 64 years with severe and moderately severe haemophilia the difference between the patients and the non-haemophiliacs was lower than the national average, but the percentage of haemophiliacs with a disability pension was higher than in the general male population. Although the same tendency was seen for the haemophiliacs, the difference between the patients and the general male population was not as great. The non-material gains such as less pain and discomfort and an improved social life would justify the 1985 level of joint impairment in patients with severe haemophilia. However, to see if this expectation becomes reality, so that the 1985 level of joint impairment in patients with severe haemophilia will diminish to the level of those with moderately severe haemophilia as shown in the figure. Of course, the number of disabled persons in the workforce will always be dependent on the general economic situation and the attitude of society towards them.

Smith et al pointed out the encouraging results of comprehensive haemophilia care programmes in the United States. They concluded that the properly treated employed patient can generate more money than his treatment costs. Schimpf and Niederberger showed in a group of German haemophiliacs that the employed patient would be able to make up roughly half the cost of treatment through contributions to the gross national product and pension savings. For The Netherlands we estimate that with an average consumption of 54 000 units of factor VIII a year the cost ($24 300) is more than the average annual income of a Dutch man ($21 900). The difference in outcome between these studies is caused by the difference in cost per unit of factor VIII in the United States (comprehensive care programmes cost 50% in France, 53% in West Germany, 39% in the United Kingdom, and 80% in the United States. It is higher, however, than in Belgium, 4% or Finland, 1.5% (E Ikkala, personal communication). The low numbers of seropositive patients in these two countries and The Netherlands can be explained by the predominant use of plasma products from local unpaid donors.

Many haemophiliacs are still unable to participate fully in employment owing to joint impairment. We expect that in the future this situation will improve as more and more young haemophiliacs grow up with better joints and muscles than the older haemophiliacs did. A much longer observation period will be needed, however, to see if this expectation becomes reality, so that the 1985 level of joint impairment in patients with severe haemophilia will diminish to the level of those with moderately severe haemophilia as shown in the figure. Of course, the number of disabled persons in the workforce will always be dependent on the general economic situation and the attitude of society towards them.

Although measures have been taken to prevent HIV infection, many haemophiliacs were infected before these could be implemented. A prevalence of seropositive patients here of 17% is low compared with 50% in France, 55% in West Germany, 39% in the United Kingdom, and 80% in the United States. It is higher, however, than in Belgium, 4% or Finland, 1.5% (E Ikkala, personal communication). The low numbers of seropositive patients in these two countries and The Netherlands can be explained by the predominant use of plasma products from local unpaid donors.

Many haemophiliacs are still unable to participate fully in employment owing to joint impairment. We expect that in the future this situation will improve as more and more young haemophiliacs grow up with better joints and muscles than the older haemophiliacs did. A much longer observation period will be needed, however, to see if this expectation becomes reality, so that the 1985 level of joint impairment in patients with severe haemophilia will diminish to the level of those with moderately severe haemophilia as shown in the figure. Of course, the number of disabled persons in the workforce will always be dependent on the general economic situation and the attitude of society towards them.

Smith et al pointed out the encouraging results of comprehensive haemophilia care programmes in the United States. They concluded that the properly treated employed patient can generate more money than his treatment costs. Schimpf and Niederberger showed in a group of German haemophiliacs that the employed patient would be able to make up roughly half the cost of treatment through contributions to the gross national product and pension savings. For The Netherlands we estimate that with an average consumption of 54 000 units of factor VIII a year the cost ($24 300) is more than the average annual income of a Dutch man ($21 900). The difference in outcome between these studies is caused by the difference in cost per unit of factor VIII in the United States (comprehensive care programmes cost 50% in France, 53% in West Germany, 39% in the United Kingdom, and 80% in the United States. It is higher, however, than in Belgium, 4% or Finland, 1.5% (E Ikkala, personal communication). The low numbers of seropositive patients in these two countries and The Netherlands can be explained by the predominant use of plasma products from local unpaid donors.
absence of the savings due to fewer admissions to hospital, less absenteeism from work or school, and lower social security payments. It is difficult to judge the success of the treatment without considering the disastrous AIDS epidemic, but the favourable trends shown by our results give us a glimpse of the promises held by the newer products and methods for the treatment of haemophiliacs.

We gratefully acknowledge the enthusiastic participation of the patients with haemophilia and the collaboration of the Dutch haemophilia treatment centres. Dr J Hermans, Department of Medical Statistics, University Hospital Leiden, kindly gave us advice on statistical matters.

The study was supported by grants from Het Praeventiefonds (28-1099) and De Stichting Haemofilia.

5 Goldsmith MF. Hemophilia, beaten on one front, is beat on others. JAMA 1986;256:3200
7 Children's Orthopedic Hospital. A total approach to treatment and rehabilitation of haemophilia. Los Angeles, California. Children's Orthopedic Hospital, 1968
9 Mansveld van Smeerdijk, J. Hemochronologic support. Rotterdam: Van Oorschot, 1986
12 Hammond EC, Horn D. Smoking and death rates. report on 44 months of follow up of 187385 men. Total mortality. JAMA 1958;166:1559-72
22 Hagen PJ. Blood products and markets. New York, Los, 1982

(Received 27 September 1988)